Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A Microbiological, Toxicological, and Biochemical Study of the Effects of Fucoxanthin, a Marine Carotenoid, on Mycobacterium tuberculosis and the Enzymes Implicated in Its Cell Wall: A Link Between Mycobacterial Infection and Autoimmune Diseases

M. Šudomová, MA. Shariati, J. Echeverría, I. Berindan-Neagoe, SM. Nabavi, STS. Hassan,

. 2019 ; 17 (11) : . [pub] 20191114

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023489

This study explored the antitubercular properties of fucoxanthin, a marine carotenoid, against clinical isolates of Mycobacterium tuberculosis (Mtb). Two vital enzymes involved in Mtb cell wall biosynthesis, UDP-galactopyranose mutase (UGM) and arylamine-N-acetyltransferase (TBNAT), were selected as drug targets to reveal the mechanism underlying the antitubercular effect of fucoxanthin. The obtained results showed that fucoxanthin showed a clear bacteriostatic action against the all Mtb strains tested, with minimum inhibitory concentrations (MIC) ranging from 2.8 to 4.1 µM, along with a good degree of selectivity index (ranging from 6.1 to 8.9) based on cellular toxicity evaluation compared with standard drug isoniazid (INH). The potent inhibitory actions of fucoxanthin and standard uridine-5'-diphosphate against UGM were recorded to be 98.2% and 99.2%, respectively. TBNAT was potently inactivated by fucoxanthin (half maximal inhibitory concentration (IC50) = 4.8 µM; 99.1% inhibition) as compared to INH (IC50 = 5.9 µM; 97.4% inhibition). Further, molecular docking approaches were achieved to endorse and rationalize the biological findings along with envisaging structure-activity relationships. Since the clinical evidence of the last decade has confirmed the correlation between bacterial infections and autoimmune diseases, in this study we have discussed the linkage between infection with Mtb and autoimmune diseases based on previous clinical observations and animal studies. In conclusion, we propose that fucoxanthin could demonstrate great therapeutic value for the treatment of tuberculosis by acting on multiple targets through a bacteriostatic effect as well as by inhibiting UGM and TBNAT. Such outcomes may lead to avoiding or decreasing the susceptibility to autoimmune diseases associated with Mtb infection in a genetically susceptible host.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023489
003      
CZ-PrNML
005      
20201214130157.0
007      
ta
008      
201125s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/md17110641 $2 doi
035    __
$a (PubMed)31739453
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šudomová, Miroslava $u Museum of Literature in Moravia, Klášter 1, 664 61 Rajhrad, Czech Republic.
245    12
$a A Microbiological, Toxicological, and Biochemical Study of the Effects of Fucoxanthin, a Marine Carotenoid, on Mycobacterium tuberculosis and the Enzymes Implicated in Its Cell Wall: A Link Between Mycobacterial Infection and Autoimmune Diseases / $c M. Šudomová, MA. Shariati, J. Echeverría, I. Berindan-Neagoe, SM. Nabavi, STS. Hassan,
520    9_
$a This study explored the antitubercular properties of fucoxanthin, a marine carotenoid, against clinical isolates of Mycobacterium tuberculosis (Mtb). Two vital enzymes involved in Mtb cell wall biosynthesis, UDP-galactopyranose mutase (UGM) and arylamine-N-acetyltransferase (TBNAT), were selected as drug targets to reveal the mechanism underlying the antitubercular effect of fucoxanthin. The obtained results showed that fucoxanthin showed a clear bacteriostatic action against the all Mtb strains tested, with minimum inhibitory concentrations (MIC) ranging from 2.8 to 4.1 µM, along with a good degree of selectivity index (ranging from 6.1 to 8.9) based on cellular toxicity evaluation compared with standard drug isoniazid (INH). The potent inhibitory actions of fucoxanthin and standard uridine-5'-diphosphate against UGM were recorded to be 98.2% and 99.2%, respectively. TBNAT was potently inactivated by fucoxanthin (half maximal inhibitory concentration (IC50) = 4.8 µM; 99.1% inhibition) as compared to INH (IC50 = 5.9 µM; 97.4% inhibition). Further, molecular docking approaches were achieved to endorse and rationalize the biological findings along with envisaging structure-activity relationships. Since the clinical evidence of the last decade has confirmed the correlation between bacterial infections and autoimmune diseases, in this study we have discussed the linkage between infection with Mtb and autoimmune diseases based on previous clinical observations and animal studies. In conclusion, we propose that fucoxanthin could demonstrate great therapeutic value for the treatment of tuberculosis by acting on multiple targets through a bacteriostatic effect as well as by inhibiting UGM and TBNAT. Such outcomes may lead to avoiding or decreasing the susceptibility to autoimmune diseases associated with Mtb infection in a genetically susceptible host.
650    _2
$a antituberkulotika $x farmakologie $7 D000995
650    _2
$a arylamin-N-acetyltransferasa $x metabolismus $7 D001191
650    _2
$a autoimunitní nemoci $x farmakoterapie $7 D001327
650    _2
$a karotenoidy $x farmakologie $7 D002338
650    _2
$a buněčné linie $7 D002460
650    _2
$a buněčná stěna $x účinky léků $x enzymologie $7 D002473
650    _2
$a lidé $7 D006801
650    _2
$a intramolekulární transferasy $x metabolismus $7 D019751
650    _2
$a izoenzymy $x metabolismus $7 D007527
650    _2
$a mikrobiální testy citlivosti $x metody $7 D008826
650    _2
$a simulace molekulového dockingu $x metody $7 D062105
650    _2
$a Mycobacterium tuberculosis $x účinky léků $x enzymologie $7 D009169
650    _2
$a tuberkulóza $x farmakoterapie $7 D014376
650    _2
$a xanthofyly $x farmakologie $7 D024341
655    _2
$a časopisecké články $7 D016428
700    1_
$a Shariati, Mohammad Ali $u Kazakh Research Institute of Processing and Food Industry (Semey Branch), Semey 071410, Kazakhstan.
700    1_
$a Echeverría, Javier $u Departamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Casilla 40, Correo 33, Santiago 9170022, Chile.
700    1_
$a Berindan-Neagoe, Ioana $u Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy "Iuliu-Hatieganu", 400337 Cluj-Napoca, Romania. MedFuture Research Center for Advanced Medicine, University of Medicine and Pharmacy "Iuliu-Hatieganu", 400349 Cluj-Napoca, Romania. Department of Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuţă", 400015 Cluj-Napoca, Romania.
700    1_
$a Nabavi, Seyed Mohammad $u Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran 14359-16471, Iran.
700    1_
$a Hassan, Sherif T S $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackého tř. 1946/1, 612 42 Brno, Czech Republic.
773    0_
$w MED00165871 $t Marine drugs $x 1660-3397 $g Roč. 17, č. 11 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31739453 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130156 $b ABA008
999    __
$a ok $b bmc $g 1595808 $s 1114165
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 17 $c 11 $e 20191114 $i 1660-3397 $m Marine drugs $n Mar. drugs $x MED00165871
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace